Reminyl Disease Interactions
There are 5 disease interactions with Reminyl (galantamine).
Cholinesterase inhibitor (applies to Reminyl) bradycardia
Major Potential Hazard, Moderate plausibility. Applicable conditions: Arrhythmias
Due to their pharmacological action, cholinesterase inhibitors can have a vagotonic effect on the sinoatrial and atrioventricular nodes producing bradycardia or heart block. Therapy with cholinesterase inhibitors should be administered cautiously in patients with preexisting bradycardia or underlying cardiac conduction abnormalities. Syncopal episodes have been reported in patients with and without cardiac abnormalities. Atropine may be used to reverse bradycardia produced by cholinesterase inhibitors.
References
- Wilcock GK, Surmon D, Forsyth D, Morgan R (1988) "Cholinergic side-effects of tetrahydroaminoacridine." Lancet, 2, p. 1305
- (2001) "Product Information. Cognex (tacrine)." Parke-Davis
- Baldessarini RJ, Gelenberg AJ (1979) "Using physostigmine safely." Am J Psychiatry, 136, p. 1608-9
- Janowsky DS, Risch SC, Huey LY, Kennedy B, Ziegler M (1985) "Effects of physostigmine on pulse, blood pressure, and serum epinephrine levels." Am J Psychiatry, 142, p. 738-40
- Dysken MW, Janowsky DS (1985) "Dose-related physostigmine-induced ventricular arrhythmia: case report." J Clin Psychiatry, 46, p. 446-7
- "Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories
- (2001) "Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc
- "Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.
- (2001) "Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals
- "Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc
- "Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics
- (2001) "Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals
- (2001) "Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals
Cholinesterase inhibitor (applies to Reminyl) bronchospasm
Major Potential Hazard, Moderate plausibility. Applicable conditions: Chronic Obstructive Pulmonary Disease, Asthma
Cholinesterase inhibitors inhibit the hydrolysis of acetylcholine. The enhanced effect of acetylcholine produces constriction of the bronchi, increased bronchial secretions, and bronchospasm. Therapy with cholinesterase inhibitors should be administered cautiously in patients with respiratory dysfunction, history of asthma or obstructive pulmonary disease. Monitoring respiratory function during dosage initiation and adjustment is recommended. Use of atropine along with discontinuation of the cholinesterase inhibitor may be required for serious respiratory distress. Neostigmine may produce more severe muscarinic side effects than does pyridostigmine and ambenonium. However, the duration of action is longest for ambenonium and shortest for edrophonium. Echothiophate iodide ophthalmic may be systemically absorbed and cautious use is recommended in these patients.
References
- Wilcock GK, Surmon D, Forsyth D, Morgan R (1988) "Cholinergic side-effects of tetrahydroaminoacridine." Lancet, 2, p. 1305
- (2001) "Product Information. Cognex (tacrine)." Parke-Davis
- "Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories
- (2001) "Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc
- "Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.
- (2001) "Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals
- "Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc
- "Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics
- (2001) "Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals
- (2001) "Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals
Cholinesterase inhibitor (applies to Reminyl) PUD
Major Potential Hazard, Moderate plausibility. Applicable conditions: Peptic Ulcer
The use of cholinesterase inhibitors is associated with an increase in gastric acid secretion and gastric contractions. Therapy with cholinesterase inhibitors should be administered cautiously in patients with peptic ulcer disease.
References
- (2001) "Product Information. Cognex (tacrine)." Parke-Davis
- "Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories
- (2001) "Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc
- "Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.
- (2001) "Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals
- "Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc
- "Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics
- (2001) "Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals
- (2001) "Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals
Galantamine (applies to Reminyl) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
In patients with moderate hepatic impairment (Child-Pugh score of 7 to 9), the dosage of galantamine should generally not exceed 16 mg/day. The use of galantamine hydrobromide tablets in patients with severe hepatic impairment (Child-Pugh score of 10 to 15) is not recommended.
References
- (2001) "Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals
- (2005) "Product Information. Razadyne (galantamine)." Johnson and Johnson Medical Inc
Galantamine (applies to Reminyl) renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
In patients with creatinine clearance of 9 to 59 mL/min, the dosage of galantamine should generally not exceed 16 mg/day. In patients with creatinine clearance less than 9 mL/min, the use of galantamine hydrobromide tablets is not recommended.
References
- (2001) "Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals
- (2005) "Product Information. Razadyne (galantamine)." Johnson and Johnson Medical Inc
Reminyl drug interactions
There are 374 drug interactions with Reminyl (galantamine).
More about Reminyl (galantamine)
- Reminyl consumer information
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: cholinesterase inhibitors
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.